We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.88%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.74B
AUM Growth
+$366M
Cap. Flow
+$279M
Cap. Flow %
10.2%
Top 10 Hldgs %
49.25%
Holding
82
New
4
Increased
18
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$84.9M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$63.4M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$54M
4
RVMD icon
Revolution Medicines
RVMD
+$41.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$41.1M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$47.6M
2
CGEM icon
Cullinan Oncology
CGEM
+$47.5M
3
VRDN icon
Viridian Therapeutics
VRDN
+$34.3M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$21.2M
5
ANNX icon
Annexon
ANNX
+$19.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYXS icon
76
Pyxis Oncology
PYXS
$169M
– –
-2,938,851
Closed -$3.94M
RCUS icon
77
Arcus Biosciences
RCUS
$3.47B
– –
-2,303,520
Closed -$47.6M
RNAC icon
78
Cartesian Therapeutics
RNAC
$222M
– –
-46,392
Closed -$1.57M
XFOR icon
79
X4 Pharmaceuticals
XFOR
$372M
– –
-44,922
Closed -$1.34M
RNTX
80
Rein Therapeutics
RNTX
$63.3M
– –
-236,835
Closed -$561K
CNCE
81
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-3,629,000
Closed -$21.2M
CALA
82
DELISTED
Calithera Biosciences, Inc
CALA
– –
-464,742
Closed -$1.52M
1 2 3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2023 Portfolio in Review

As of Q1 2023, BVF Inc held 82 positions worth $2.74B, up 15% from $2.37B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

BVF Inc deployed $279M of net new capital in Q1 2023, opening 4 new positions and adding to 18 existing holdings. Its largest new stake was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $47.5M trimmed.

  • BVF Inc's largest Q1 2023 buy was Protagonist Therapeutics: 3,775,900 shares worth $86.8M.
  • BVF Inc added most to Lakefront Biotherapeutics American Depositary Shares in Q1 2023, an estimated $84.9M increase.
  • BVF Inc's biggest Q1 2023 reduction was Cullinan Oncology, cutting an estimated $47.5M.
  • BVF Inc fully exited Arcus Biosciences in Q1 2023, selling an estimated $47.6M.
  • BVF Inc's ten largest holdings make up 49% of its $2.74B portfolio in Q1 2023.
  • BVF Inc opened 4 new positions and closed 10 in Q1 2023.
  • BVF Inc's portfolio value rose 15% quarter-over-quarter to $2.74B.

Based on BVF Inc's 13F filing for Q1 2023, filed 15 May 2023.